These findings suggested that EV, an antibody-drug conjugate targeting Nectin-4, would be effective in a broad range of patients with UTUC irrespective of the PD-L1 expression level. This evidence concerns the gene NECTIN4 and renal pelvis/ureter urothelial carcinoma.